STAAR Surgical Company (STAA)
Healthcare · NGM
Price as at 1 Oct 2026, 01:56 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
STAAR Surgical Company trades at $22.61, which is 59% above the $9.18 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 44 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
STAA earnings and analyst estimates
Recommendation mix, 10 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
STAA passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Steve Cohen, Point72 Asset Management, L.P.$69.93M · 0.1% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$9.77M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$6.70M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$3.16M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$631.3K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in STAA
Trades in STAA disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
STAA peers
The largest companies in the same industry (Medical Instruments & Supplies), then in the same sector.
- MDLN Medline Inc.
- RSMDF ResMed Inc.
- SRT3.DE Sartorius Aktiengesellschaft
- SOLV Solventum Corporation
- BAX Baxter International Inc.
- RGEN Repligen Corporation
- AVTR Avantor, Inc.
- TFX Teleflex Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is STAAR Surgical Company (STAA) undervalued?
Against our fair value estimate of $9.18, STAA at $22.61 is 59% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own STAA?
7 of the institutions we track reported a position in STAA in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its STAA data?
Fundamentals for STAA come from company filings and exchange data, as listed on NGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:56 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for STAA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.